このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Ultragenyx Pharmaceutical マネジメント
マネジメント 基準チェック /24
Ultragenyx Pharmaceutical'sの CEO はEmil Kakkisで、 Apr2010年に任命され、 の在任期間は 14.17年です。 の年間総報酬は$ 13.08Mで、 6.3%給与と93.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.64%を直接所有しており、その価値は$ 94.98M 。経営陣と取締役会の平均在任期間はそれぞれ8.5年と8.2年です。
主要情報
Emil Kakkis
最高経営責任者
US$13.1m
報酬総額
| CEO給与比率 | 6.3% |
| CEO在任期間 | 14.4yrs |
| CEOの所有権 | 2.9% |
| 経営陣の平均在職期間 | 8.7yrs |
| 取締役会の平均在任期間 | 8.4yrs |
経営陣の近況
Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$585m |
| Mar 31 2024 | n/a | n/a | -US$613m |
| Dec 31 2023 | US$13m | US$824k | -US$607m |
| Sep 30 2023 | n/a | n/a | -US$635m |
| Jun 30 2023 | n/a | n/a | -US$721m |
| Mar 31 2023 | n/a | n/a | -US$719m |
| Dec 31 2022 | US$12m | US$796k | -US$707m |
| Sep 30 2022 | n/a | n/a | -US$678m |
| Jun 30 2022 | n/a | n/a | -US$506m |
| Mar 31 2022 | n/a | n/a | -US$470m |
| Dec 31 2021 | US$10m | US$769k | -US$454m |
| Sep 30 2021 | n/a | n/a | -US$356m |
| Jun 30 2021 | n/a | n/a | -US$351m |
| Mar 31 2021 | n/a | n/a | -US$204m |
| Dec 31 2020 | US$5m | US$759k | -US$187m |
| Sep 30 2020 | n/a | n/a | -US$256m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$425m |
| Dec 31 2019 | US$7m | US$714k | -US$403m |
| Sep 30 2019 | n/a | n/a | -US$397m |
| Jun 30 2019 | n/a | n/a | -US$371m |
| Mar 31 2019 | n/a | n/a | -US$325m |
| Dec 31 2018 | US$5m | US$680k | -US$198m |
| Sep 30 2018 | n/a | n/a | -US$192m |
| Jun 30 2018 | n/a | n/a | -US$183m |
| Mar 31 2018 | n/a | n/a | -US$204m |
| Dec 31 2017 | US$7m | US$638k | -US$302m |
報酬と市場: Emilの 総報酬 ($USD 13.08M ) は、 US市場 ($USD 6.83M ) の同規模の企業の平均を上回っています。
報酬と収益: Emilの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Emil Kakkis (64 yo)
14.4yrs
在職期間
US$13,077,993
報酬
Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 146.1m | |
| Executive VP of Corporate Strategy & CFO | less than a year | US$5.94m | データなし | |
| Chief Legal Officer & Executive VP of Corporate Affairs | 8.3yrs | US$4.04m | 0.017% $ 833.2k | |
| Chief Quality Operations Officer & Executive VP of Translational Sciences | 9.2yrs | US$4.05m | 0.051% $ 2.5m | |
| Executive VP & Chief Commercial Officer | no data | US$4.07m | 0.025% $ 1.2m | |
| Senior VP | 10.7yrs | データなし | 0.019% $ 968.0k | |
| Chief Human Resources Officer & Executive VP | 4yrs | データなし | データなし | |
| Chief Business Officer & Executive VP | 12.8yrs | US$2.46m | 0.23% $ 11.4m | |
| Senior Vice President of Business Development & Alliance Management | 6.5yrs | データなし | データなし | |
| Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 9.3yrs | US$4.24m | 0.044% $ 2.2m | |
| Senior Vice President of Corporate Strategy & Finance | no data | データなし | データなし | |
| Chief Medical Officer & Executive VP | 1.3yrs | データなし | 0.020% $ 1.0m |
8.7yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: RAREの経営陣は経験豊富で経験豊富です（平均在職期間は8.5年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 146.1m | |
| Independent Non-Executive Chairman | 9.4yrs | US$499.89k | 0.023% $ 1.2m | |
| Independent Director | 10.7yrs | US$479.89k | 0.016% $ 808.6k | |
| Independent Director | 5.6yrs | US$466.89k | 0.016% $ 808.6k | |
| Independent Director | 7.4yrs | US$459.89k | 0.021% $ 1.1m | |
| Independent Director | 3.3yrs | US$469.39k | 0.0058% $ 290.8k | |
| Independent Director | 9.6yrs | US$482.39k | 0.023% $ 1.2m | |
| Independent Director | 2.4yrs | US$460.39k | 0.011% $ 575.5k |
8.4yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: RAREの 取締役会 は 経験豊富 であると考えられます ( 8.2年の平均在任期間)。